The Medicines Company is conducting several development programs with planned and executed clinical trials. We believe our pipeline of products in development can satisfy unmet medical needs in the acute and intensive care hospital market.
Cangrelor — An investigational antiplatelet agent.
IonsysTM — An investigational fentanyl iontophoretic transdermal system.
Oritavancin — An investigational hospital-based broad spectrum antibiotic.
MDCO-216 — An investigational, reverse cholesterol transport that is a naturally occurring variant of a protein called ApoA-I found in human high-density lipoprotein.
ALN-PCSK — An investigational siRNA-based LDL lowering agent.